Neoplastic Condition Affecting Patents (Class 514/19.2)
-
Patent number: 8669230Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells which can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: October 29, 2010Date of Patent: March 11, 2014Assignee: Immatics Biotechnologies GmbHInventors: Harpreet Singh, Steffen Walter, Toni Weinschenk, Norbert Hilf, Oliver Schoor, Claudia Lemmel
-
Publication number: 20140065094Abstract: The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.Type: ApplicationFiled: December 27, 2012Publication date: March 6, 2014Applicant: Creabillis Therapeutics S.P.A.Inventors: Silvio TRAVERSA, Chiara LORENZETTO, Valentina MAINERO, Sebastiano MORENA, Silvano FUMERO, Luca BECCARIA
-
Publication number: 20140066386Abstract: The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, wherein R is H, halo, or C1-C6 alkyl; R? is C1-C6 alkyl; or a pharmaceutically acceptable salt thereof; and optionally a pharmaceutically acceptable excipient.Type: ApplicationFiled: February 7, 2013Publication date: March 6, 2014Applicant: GILEAD CALISTOGA LLCInventor: Gilead Calistoga LLC
-
Patent number: 8663651Abstract: The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful for immunomodulation.Type: GrantFiled: December 23, 2007Date of Patent: March 4, 2014Assignee: Biokine Therapeutics Ltd.Inventors: Amnon Peled, Michal Begin, Katia Beider, Michal Abraham
-
Patent number: 8664181Abstract: A prodrug comprising at least two different pharmaceutically and/or diagnostically active compounds independently bound by cleavable linkers and a protein-binding moiety which is capable of binding to carrier a molecule is described.Type: GrantFiled: February 15, 2008Date of Patent: March 4, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Irmgard Merfort
-
Patent number: 8663636Abstract: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.Type: GrantFiled: April 13, 2012Date of Patent: March 4, 2014Assignee: MedImmune, LLCInventors: Ian Foltz, David Jenkins, Vahe Bedian
-
Patent number: 8658591Abstract: Disclosed herein are PACE4 inhibitors, compositions comprising PACE4 inhibitors and their uses thereof for lowering PACE4 activity, reducing cell proliferation, reducing tumor growth, reducing metastasis formation, preventing and/or treating cancer. Also provided are methods for lowering PACE4 activity, reducing the proliferation of a cell, reducing tumor growth and/or treating and preventing cancer. Methods for screening PACE4 inhibitors and cell proliferation inhibitors are further provided.Type: GrantFiled: July 6, 2009Date of Patent: February 25, 2014Inventors: Robert Day, Martin Fugère, Witold A. Neugebauer
-
Publication number: 20140050803Abstract: Described herein are compositions and methods for the prognosis, prevention and treatment of melanoma or melanoma associated symptoms. The compositions are microRNA molecules associated with melanoma or with melanoma brain tropism, as well as various nucleic acid molecules relating thereto or derived therefrom.Type: ApplicationFiled: April 13, 2011Publication date: February 20, 2014Applicant: NEW YORK UNIVERSITYInventors: Eva Hernando, Moshe Hoshen, Iman Osman, Avital Gaziel-Sovran, Miguel F. Segura
-
Patent number: 8653031Abstract: We describe preparation of compounds of an AT1 receptor antagonist(s) and Angiotensin (1-7), for example, Angiotensin-(1-7) losartanate and analogues thereof, and/or mixtures of these systems, pharmaceutical compositions thereof and use of their derivative products. Cyclodextrins and derivatives thereof may be used for the micro-encapsulation of compounds, for example, Angiotensin (1-7) losartanate, liposomes and biodegradable polymers and/or mixtures of these systems and/or derivative products for the obtainment of nano- or microparticles as controlled or sustained release devices of Ang-(1-7) losartanate and analogues and/or mixtures thereof. The compounds may be used as agents for treating or preventing hypertension, cardiovascular diseases, heart hypertrophy, heart failure, coronary diseases, such as angina pectoris, endothelial disorder or endothelial lesions, as a consequence, for example, of atherosclerosis processes or in association with diabetes mellitus.Type: GrantFiled: October 30, 2006Date of Patent: February 18, 2014Assignee: Universidade Federal de Minas GeraisInventors: Rubén Dario Sinisterra Millán, Cynthia Fernades Ferreira Santos, Robson Augusto Souza Dos Santos, Ivana Silva Lula, Frederico Barros De Sousa, Pedro Pires Goulart Guimaraes, Angelo Márcio Leite Denadai
-
Patent number: 8648047Abstract: Pharmaceutical compositions and methods for sensitizing multi-drug resistant cancer or radiation resistant cancer cells to chemotherapeutic agents are provided. Compositions include ligands of hyaluronan receptors, including glycosaminoglycans such as hyaluronan oligomers and derivatives of these oligomers, hyaluronan binding proteins, antibodies specific for hyaluronan receptors, hyaluronan mimetics, inhibitors of hyaluronan synthesis, and stimulators of hyaluronan degradation.Type: GrantFiled: December 28, 2011Date of Patent: February 11, 2014Assignee: Tufts UniversityInventors: Bryan P. Toole, Suniti Misra, Shibnath Ghatak
-
Patent number: 8648045Abstract: The present invention relates generally to the mitochondrial protein, voltage-dependent anion channel (VDAC), polynucleotides encoding same and variants thereof, as well as peptide fragments, peptide derivatives and analogs. In particular, the present invention is directed to VDAC1 and specific amino acid and polynucleotide sequences thereof useful in inducing or regulating apoptosis and to pharmaceutical compositions comprising same useful in the treatment of diseases associated with aberrant apoptosis.Type: GrantFiled: February 15, 2012Date of Patent: February 11, 2014Assignee: Ben Gurion University of the Negev Research and Development Authority Ltd.Inventors: Varda Shoshan-Barmatz, Salah Abu-Hamad, Laetitia Arzoine, Hilal Zaid
-
Patent number: 8642555Abstract: The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.Type: GrantFiled: March 9, 2010Date of Patent: February 4, 2014Assignee: KTB Tumorforschungsgesellschaft mbHInventors: Felix Kratz, Andre Warnecke, Bakheet Elsadek
-
Patent number: 8642580Abstract: Compounds which are ?-halogenoacryloyl distamycin derivatives of formula (I) wherein R1 is a bromine or chlorine atom; R2 is a distamycin or distamycin-like framework as set forth in the specification; or a pharmaceutically acceptable salt thereof; are cytotoxic agents particularly effective in the treatment of tumors over expressing GSH/GSTs system and which are poorly responsive or even resistant to conventional antitumor therapies.Type: GrantFiled: June 20, 2001Date of Patent: February 4, 2014Assignee: Nerviano Medical Sciences S.R.L.Inventors: M. Cristina Geroni, Paolo Cozzi, Italo Beria
-
Publication number: 20140017167Abstract: The present invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in inducing cell death and/or inhibiting the growth and/or proliferation of cells associated with a solid tumour, wherein the cells express IL1RAP. A related aspect of the invention provides agents comprising or consisting of a binding moiety with specificity for interleukin-1 receptor accessory protein (IL1RAP) for use in detecting pathological cells associated with a solid tumour, wherein the cells express IL1RAP. Further provided are pharmacological compositions comprising the agents of the invention and methods of using the same.Type: ApplicationFiled: January 19, 2012Publication date: January 16, 2014Applicant: CANTARGIA ABInventors: Thoas Fioretos, Marcus Jaras
-
Publication number: 20140017196Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.Type: ApplicationFiled: September 16, 2013Publication date: January 16, 2014Applicant: BIOSUCCESS BIOTECH CO., LTD.Inventors: Zheng Tao HAN, Hung-Fong CHEN
-
Patent number: 8629096Abstract: This invention relates to a method for stimulation or an activation of immunological function directed to activate natural killer cells and macrophages or increase production of serum antibody in a patient in need of such stimulation or activation, comprising administering an isolated and/or purified polypeptide of a fungal immunomodulatory protein. This invention also relates to a method for suppressing proliferation of a cancer cell and a method for suppressing a tumor cell mobility, comprising providing to the tumor cell a purified polypeptide of a fungal immunomodulatory protein.Type: GrantFiled: March 16, 2012Date of Patent: January 14, 2014Assignee: Yeastern Biotech Co., Ltd.Inventors: Jiunn-Liang Ko, Tzu-Chih Chen
-
Patent number: 8623828Abstract: The present invention provides mesothelin peptide fragments corresponding to the CA125 binding site of mesothelin. The peptide fragments find use in disrupting the binding interaction between mesothelin and CA 125, for example, in the treatment and prevention of cancers that require the interaction of mesothelin and CA125 for growth, progression and/or metastasis.Type: GrantFiled: December 5, 2008Date of Patent: January 7, 2014Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Mitchell Ho, Ira Pastan, Osamu Kaneko, Byungkook Lee
-
Patent number: 8623829Abstract: The present invention provides peptides having an amino acid sequence as set forth in SEQ ID NO: 19, 22, 30, 34, 344, 358, 41, 44, 46, 48, 78, 376, 379, 80, 100, 101, 110, 111, 387, 112, 394, 114, 116, 117, 121, 395, 133, 135, 137, 426, 143, 147, 148, 149, 150, 152, 153, 154, 156, 160, 161, 162, 163, 166, 174, 178, 186, 194, 196, 202, 210, 213, 214, 217, 223, 227, 228, 233, 254, 271, 272 or 288, as well as peptides having the above-mentioned amino acid sequences in which 1, 2, or several (e.g., up to 5) amino acids are substituted, deleted, or added, provided the peptides possess cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing a disease associated with over-expression of the CDH3, EPHA4, ECT2, HIG2, INHBB, KIF20A, KNTC2, TTK and/or URLC10, e.g. cancers containing as an active ingredient one or more of these peptides. The peptides of the present invention find further utility as vaccines.Type: GrantFiled: May 4, 2012Date of Patent: January 7, 2014Assignee: Oncotherapy Science, Inc.Inventors: Takuya Tsunoda, Ryuji Ohsawa, Sachiko Yoshimura
-
Publication number: 20140004040Abstract: Compositions and methods for targeted delivery to and detection of sites of neovascular growth, including tumor vasculature, are provided. Compositions include polypeptides conjugated to or complexed with a bioactive compound, wherein the polypeptide is capable of binding to an OEC or a circulating progenitor thereof. Methods for identifying additional polypeptides with the same binding characteristics are further provided. Methods for targeted delivery of a bioactive compound to a site of neovascular growth are provided in which polypeptides capable of binding OECs or progenitors thereof are conjugated to or complexed with the bioactive compound and administered to a subject in need thereof. Methods for detecting neovascular growth are also provided, wherein the polypeptides conjugated to or complexed with a detectable label are administered to a subject and the label is detected.Type: ApplicationFiled: December 1, 2011Publication date: January 2, 2014Applicants: North Carolina State University, The University of North Carolina at Chapel HillInventors: Cam Patterson, Anka N. Veleva
-
Publication number: 20140005117Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: ApplicationFiled: August 30, 2013Publication date: January 2, 2014Applicant: Morehouse School of MedicineInventors: Vincent Craig BOND, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Patent number: 8617514Abstract: The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as well as methods of imaging various tissues. The liposome complexes are useful for encapsulation of imaging agents, for example, for use in magnetic resonance imaging. The specificity of the delivery system is derived from the targeting antibodies or antibody fragments.Type: GrantFiled: October 20, 2006Date of Patent: December 31, 2013Assignee: Georgetown UniversityInventors: Esther H. Chang, Kathleen F. Pirollo
-
Patent number: 8614192Abstract: It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53 activator. In particular embodiments, the p53 activator blocks the interaction between DM2 or DMX and p53. As the p53 activator induces ocular cancer cell death, a method for preventing or treating ocular cancer is also provided.Type: GrantFiled: July 24, 2007Date of Patent: December 24, 2013Assignees: Leiden University Medical Center, Flanders Interuniversity Institute for Biotechnology, VIB, St. Jude Children's Research HospitalInventors: Michael A. Dyer, Jean-Christophe Marine, Aart Gerrit Jochemsen
-
Patent number: 8614176Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.Type: GrantFiled: October 13, 2010Date of Patent: December 24, 2013Assignee: OncoTherapy Science, Inc.Inventors: Hideaki Tahara, Takuya Tsunoda, Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
-
Patent number: 8609613Abstract: The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.Type: GrantFiled: July 18, 2012Date of Patent: December 17, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Yan Chen, Elena Getmanova, Martin C. Wright, Alan S. Harris, Ai Ching Lim, Jochem Gokemeijer, Lin Sun, Michael Wittekind
-
Publication number: 20130330399Abstract: The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises (a) a legumain-targeting lipid component, (b) a zwitterionic lipid component; (c) an amino-substituted lipid component; (d) a neutral lipid component; and (e) polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalenetly attached to a legumain-binding moiety.Type: ApplicationFiled: September 2, 2011Publication date: December 12, 2013Inventors: Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
-
Patent number: 8603985Abstract: The NSAID, sulindac and/or its metabolites and derivatives, in combination with hydrogen peroxide or another oxidizing agent, such as arsenic trioxide that generates reactive oxygen species (ROS), significantly enhances the killing of cancer cells. This effect occurs at concentrations of each compound that individually have little or no activity directed against cancer cells. A skin cream has been developed and used to treat skin cancer and precancerous skin growths that effectively removes the lesions with no effect on surrounding normal skin.Type: GrantFiled: April 14, 2010Date of Patent: December 10, 2013Assignee: CHS Pharma, IncInventors: Herbert Weissbach, Lionel Resnick, David Binninger
-
Patent number: 8598126Abstract: The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification.Type: GrantFiled: April 7, 2009Date of Patent: December 3, 2013Assignee: DKFZ Deutsches Krebsforschungszentrum, Stiftung des offentlichen RechtsInventors: Felix Hoppe-Seyler, Karin Hoppe-Seyler, Susanne Kintscher
-
Patent number: 8597645Abstract: The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation.Type: GrantFiled: October 6, 2011Date of Patent: December 3, 2013Assignee: New York UniversityInventors: Robert Schneider, Sumayah Jamal
-
Patent number: 8598125Abstract: The present invention provides the peptide of (A) or (B) below, and methods of using the peptide: (A) a peptide including the amino acid sequence of SEQ ID NO: 1 or 2, (B) a peptide which includes the amino acid sequence of SEQ ID NO: 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows killer T cell-inducing activity.Type: GrantFiled: June 13, 2008Date of Patent: December 3, 2013Assignee: Onco Therapy Science, Inc.Inventors: Yasuharu Nishimura, Michiko Harao, Takuya Tsunoda, Yusuke Nakamura
-
Publication number: 20130315973Abstract: The present invention features biocompatible devices having a surface thereof coated with a composition that includes a tribonectin, and methods of making the devices. The tribonectin may, e.g., reduce microbial growth on or attachment to the surface of the biocompatible device.Type: ApplicationFiled: May 16, 2012Publication date: November 28, 2013Inventor: Gregory D. Jay
-
Publication number: 20130316957Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: ApplicationFiled: August 1, 2013Publication date: November 28, 2013Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20130316959Abstract: C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.Type: ApplicationFiled: July 10, 2013Publication date: November 28, 2013Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Carol A. Feghali-Bostwick, Yukie Yamaguchi
-
Patent number: 8586543Abstract: The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.Type: GrantFiled: August 17, 2009Date of Patent: November 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Ahmed A. Samatar, Brian Long, Priya Dayananth, Diane Levitan, Marsha Smith
-
Publication number: 20130302357Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: ApplicationFiled: March 14, 2013Publication date: November 14, 2013Inventors: Wei Li, Nathan Elliott Fishkin, Robert Yongxin Zhao, Michael Louis Miller, Ravi V.J. Chari
-
Patent number: 8580744Abstract: A method of treating a mammal prophylactically to prevent neoplastic development comprises administering to the mammal a therapeutic vaccine comprising venom and at least one adjuvant. The method optionally further comprises administering to the mammal at least one other therapeutically effective agent, e.g., an anti-inflammatory agent.Type: GrantFiled: April 11, 2012Date of Patent: November 12, 2013Inventor: Elizabeth Shanahan-Prendergast
-
Patent number: 8575107Abstract: Clusterin-derived peptides or homologues or derivatives thereof, pharmaceutical compositions including the same, methods of manufacturing the peptides, homologues, derivatives thereof and compositions including the same, and methods of treating conditions including administering the peptides, homologues, derivatives thereof and compositions including the same, are provided. Also provided are nucleotide sequences encoding the peptides, homologues, derivatives thereof and compositions including the same, antibodies directed to epitopes thereof and fusion proteins including the same.Type: GrantFiled: January 22, 2009Date of Patent: November 5, 2013Assignee: Compugen Ltd.Inventors: Yossef Kliger, Ofer Levy, Itamar Borukhov, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Zohar Tiran, Anat Oren, Amir Toporik
-
Patent number: 8575109Abstract: The present invention provides novel, modified pokeweed antiviral proteins, nucleic acids that encode the proteins, conjugates that incorporate the proteins, and methods to make and use the proteins. The present invention also provides methods to administer the conjugates to animals, for the purpose of directing toxin to particular cells.Type: GrantFiled: July 15, 2009Date of Patent: November 5, 2013Assignees: Cedus, Inc., Colorado State University Research FoundationInventors: Eric R. Weber, Torrance M. Nett
-
Patent number: 8569244Abstract: An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below: (A) a peptide including the amino acid sequence of any one of SEQ ID NOs: 1 to 3; (B) a peptide which includes the amino acid sequence of any one of SEQ ID NOs: 1 to 3, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows cytotoxic (killer) T cell-inducing activity.Type: GrantFiled: August 12, 2008Date of Patent: October 29, 2013Assignee: OncoTherapy Science, Inc.Inventors: Yasuharu Nishimura, Kazunori Yokomine, Takuya Tsunoda, Yusuke Nakamura
-
Patent number: 8563506Abstract: Novel peptides that inhibit the release of microparticles from cells are disclosed. The peptide contains at least one VGFPV motif at the N-terminal and has a length of 10-100 amino acids. Also disclosed is polynucleotide encoding the peptide, expression vectors carrying the polynucleotide, and methods for treating AIDS and tumors using the novel peptides.Type: GrantFiled: December 4, 2012Date of Patent: October 22, 2013Assignee: Morehouse School of MedicineInventors: Vincent Craig Bond, Michael Powell, Ming Bo Huang, Syed Ali, Andrea D. Raymond, Martin Neville Shelton, Francois Jean Villinger
-
Patent number: 8557778Abstract: Cell permeable peptides derived from MLL that block the interaction of MLL with menin for the treatment of acute myeloid and acute lymphoid leukemia are disclosed. Small molecules interfere with the interaction of MLL with any of its binding partners.Type: GrantFiled: July 18, 2012Date of Patent: October 15, 2013Assignee: The University of ChicagoInventor: Michael J. Thirman
-
Patent number: 8557777Abstract: The present invention is directed to prostate specific antigen (PSA) and tumor endothelial marker 8 (TEM8) peptide compositions and methods for treating cancer with the compositions.Type: GrantFiled: March 6, 2012Date of Patent: October 15, 2013Assignee: The Board of Trustees of the University of IllinoisInventors: Supriya M. Perambakam, David J. Peace
-
Publication number: 20130266518Abstract: Methods and compositions for using tumor targeting compounds bound to microbubbles to facilitate drug delivery and diagnostic imaging at tumor sites.Type: ApplicationFiled: June 5, 2013Publication date: October 10, 2013Inventors: Sidney Hecht, Marek Belohlavek
-
Patent number: 8551951Abstract: The invention provides pharmaceutical compositions and method for inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia (BPH). In one embodiment the pharmaceutical composition includes human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof. In another embodiment, the pharmaceutical composition includes a mixture of human rHuPSP94, antigenic portions thereof, and functionally equivalent polypeptides thereof and an anticancer drug which may be administered in an appropriate dosage form, dosage quantity and dosage regimen to a patient suffering from, for example of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, benign prostate hyperplasia, or (BPH) gastrointestinal cancer.Type: GrantFiled: January 22, 2010Date of Patent: October 8, 2013Assignee: Aenorasis SA Pharmaceuticals and Medical DevicesInventors: Seema Garde, Chandra J. Panchal, Madhulika Baijal-Gupta, Jennifer Fraser, Salam Kadhim
-
Publication number: 20130261064Abstract: The present application relates to new derivatives of monomethylauristatin F, substituted on the N terminus by a carboxyalkyl group, processes for preparing these derivatives, their use for the treatment and/or prevention of diseases and to produce medication for the treatment and/or prevention of diseases, particularly hyperproliferative and/or angiogenic disorders such as cancer disorders, for example. Such treatments can occur as monotherapies or in combination with other medication or further therapeutic measures.Type: ApplicationFiled: September 26, 2011Publication date: October 3, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Hans-Georg Lerchen, Sherif El Sheikh, Beatrix Srelte Ludwig, Sven Golfier, Joachim Schumacher, Joan Mark Gnoth, Ursula Krenz
-
Publication number: 20130259929Abstract: The present invention concerns the use of a phosphopeptide able to block HER3/p85 interaction for the treatment of HER2 hyper-expressing tumours, such as, for example, metastatic mammary tumour, possibly in combination with other anti-tumour agents like, for example, trastuzumabType: ApplicationFiled: September 29, 2011Publication date: October 3, 2013Inventors: Rita Falcioni, Valentina Folgiero, Selene Eleonora Di Carlo, Giulia Bon
-
Patent number: 8546524Abstract: Disclosed is an isolated or purified polypeptide or peptidomimetic comprising an amino acid sequence of a portion of a Smoothened (SMO) protein, wherein the portion comprises an amino acid sequence of any of the intracellular loops of the SMO protein, a functional fragment thereof, or a functional variant of either the portion or the functional fragment, wherein the functional fragment comprises at least 7 contiguous amino acids of the intracellular loops, and wherein the functional fragment or functional variant inhibits proliferation of a diseased cell, or a fatty acid derivative thereof. Related conjugates, nucleic acids, recombinant expression vectors, host cells, and pharmaceutical compositions are further provided.Type: GrantFiled: May 14, 2012Date of Patent: October 1, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nadya Tarasova, Michael Dean, Hong Lou
-
Publication number: 20130243697Abstract: Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.Type: ApplicationFiled: April 17, 2012Publication date: September 19, 2013Inventors: Mark L. Tykocinski, Jui-Han Huang
-
Patent number: 8536132Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.Type: GrantFiled: February 10, 2011Date of Patent: September 17, 2013Assignees: Sanford-Burnham Medical Research Institute, The Regents of the University of CaliforniaInventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
-
Patent number: 8530428Abstract: Methods for treating cancer (e.g., metastatic cancer to the lung or chronic lymphocytic leukemia) in patients are described that include administrating an aerosolized granulocyte macrophage colony stimulating factor to the patients. Methods for stimulating an immune response in patients also are described.Type: GrantFiled: March 7, 2008Date of Patent: September 10, 2013Assignee: Mayo Foundation for Medical Education and ResearchInventor: Svetomir N. Markovic
-
Patent number: 8529900Abstract: The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer.Type: GrantFiled: April 14, 2009Date of Patent: September 10, 2013Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Assistance Publique Hopitaux de ParisInventors: Marco Alifano, Patricia Forgez